Freeline Therapeutics IPO

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases.

Register for Details

For more details on financing and valuation for Freeline Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Freeline Therapeutics's ticker symbol?


What is Freeline Therapeutics's stock price?

6.34 as of 11/29/23

Learn more about Freeline Therapeutics

Forge green plus iconForge green minus icon

What is Freeline Therapeutics funding to date?

Freeline Therapeutics has raised $205.53MM to date.
Forge green plus iconForge green minus icon

When was Freeline Therapeutics founded?

Freeline Therapeutics was founded in 2015.
Updated on: Nov 15, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.